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BACKGROUND. Research on castration resistant prostate cancer (CRPC) has focused
primarily on functional alterations of the androgen receptor (AR). However, little is known
about the loss of AR gene expression itself and the possible contribution of AR negative cells
to CRPC.
METHODS. Human and murine prostate cancer tissue microarrays (TMAs) were evaluated
with antibodies specific for E2F1, DNA methyltransferase 1 or AR. The human prostate cancer
TMA consisted of clinical samples ranging from normal tissue to samples of metastatic disease.
The murine TMA was comprised of benign, localized or metastatic prostate cancer acquired
from TRAMP mice treated with castration and/or 50-Aza-20-deoxycytidine (5Aza).
RESULTS. Immunohistochemical analysis revealed increased nuclear DNMT1 staining in
localized PCa (P < 0.0001) and metastatic PCa (P < 0.0001) compared to normal tissue.
Examination of specific diagnoses revealed that Gleason seven tumors exhibited greater
nuclear DNMT1 staining than Gleason six tumors (P < 0.05) and that metastatic tissue
exhibited greater levels of nuclear DNMT1 than Gleason seven tumors (P < 0.01). Evaluation
of the murine tissue cores revealed that 8.2% and 8.1% of benign tissue cores stained positive
for E2F1 and DNMT1 respectively, while 97.0% were AR positive. Conversely, 81% and 100%
of tumors were positive for E2F1and DNMT1 respectively. This was in stark contrast to only
18% of tumors positive for AR. Treatment of mice with 5Aza reduced DNMT1 staining by
30%, while AR increased by 27%.
CONCLUSIONS. These findings demonstrate that the E2F1/DNMT1 inhibitory axis of AR
transcription is activated during the emergence of CRPC. Prostate 73:1776–1785, 2013.
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INTRODUCTION
Castration resistant prostate cancer (CRPC) contin-
ues to be the leading cause of prostate cancer related
deaths. Research on this disease has focused primarily
on the functional deregulation of androgen receptor
(AR) during progression to CRPC, however, little
is known about the loss of AR gene expression itself
and the possible contribution of AR negative cells to
CRPC. A significant decrease in AR expression coinci-
dent with the onset of CRPC has been demonstrated in
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prostate tumors recurring after anti androgen
therapy [1]. Immunohistochemical (IHC) analysis has
also revealed a significant decrease in AR expression
in prostate tumors from patients who failed com-
bination hormone therapy compared to untreated
individuals [2]. More recently, we reported that meta-
static lesions from CRPC patients revealed a signifi-
cant reduction in AR staining when compared to
hormone na€ıve cases [3]. Taken together, these findings
suggest that reduced AR expression may contribute to
the development of CPRC; however, complete elucida-
tion of these inhibitory mechanisms has not been fully
described.
E2F1 is a transcription factor that plays a role in
driving S-phase transit of the cell cycle during cellular
proliferation [4]. A genome wide microarray study
evaluating gene regulatory signatures associated with
cancer verified that more than half of the signatures
analyzed were E2F1 target genes [5]. Using a metastat-
ic prostate cancer tissue microarray (TMA), we found
significant increases in E2F1 staining in metastatic
CRPC samples compared to hormone na€ıve cases that
were significantly associated with concurrent reduc-
tion of AR staining in the same samples [3]. Another
study reported that E2F1 cDNA was elevated in
advanced prostate cancer and lymph node metastases
and also demonstrated that the majority of the tumor
cell nuclei in tumors associated with biochemical
recurrence exhibited strong E2F1 staining [6]. We had
previously reported that the activation of the DNMT1
gene is specifically mediated by E2F1 in several
prostate cancer models and that catalytic inhibition of
DNMT1 prevents prostate tumor formation and meta-
static progression [7]. Based on these studies, several
mechanisms by which elevated E2F1 drives prostate
cancer progression have been postulated including a
prolonged hyper-proliferative state of tumor cells or
the epigenetic silencing of tumor suppressor genes
through aberrant activation of DNMT1.
DNMT1 is a member of the DNA methyltransferase
family that is responsible for maintaining methylation
patterns located in CG dinucleotide-rich regions with-
in genomic DNA. Methylation of DNA contributes to
genetic silencing by cooperating with other epigenetic
mechanisms to either block transcriptional complexes
or induce conformational changes in the DNA struc-
ture that inhibit transcription [8]. Aberrant DNMT1
expression and function are associated with the pro-
gression of various human tumors and elevated
DNMT1 levels have been reported in the metastatic
progression of many human cancers [9,10]. DNMT1
protein has also been reported to be elevated in
prostate tumors compared to benign prostate tissue
and that DNMT1 mRNA expression is increased in
advanced prostate cancer and in experimental cell-
based models that recapitulate CRPC [11,12]. A ge-
nome wide cDNA microarray study conducted by
Tomlins et al. [13] was the first to reveal elevated
DNMT1 cDNA in CRPC compared to primary pros-
tate cancer; however, little more is known about the
relationship between DNMT1 and the development of
CRPC in patients. While it does not fully recapitulate
the histo-pathological progression of human prostate
cancer, the murine transgenic adenocarcinoma of the
mouse prostate (TRAMP) model has been very useful
in studies examining increased DNMT1 expression
during the progression to poorly differentiated and
metastatic disease [13,14]. Using this model, we have
shown that the catalytic inhibition of DNMT with
5Aza treatment prevented both the histo-pathological
progression and associated lethality in TRAMP
mice [7]. Extensive efforts to reveal molecular markers
in vastly heterogeneous prostate cancer cases have
identified a number of consistently hyper-methylated
genes that may represent the catalytic signature of
DNMT1 in prostate cancer progression [15]. Collec-
tively, these observations support a functional role for
DNMT1 during prostate cancer progression that may
include, directly or indirectly, the repression of AR
gene transcription in the development of CRPC.
We have recently described a novel mechanism by
which AR transcription is repressed through E2F1-
mediated induction of the DNA methyltransferase 1
(DNMT1) gene [16]. Based on this evidence, we
postulated that this mechanism may play a role in the
repression of AR in a subset of CRPC patients. To help
establish the existence of this regulatory axis in CRPC,
we examined the expression of E2F1, DNMT1, and AR
in samples of human CRPC and in murine models of
CRPC.
MATERIALSANDMETHODS
HumanProstate Cancer Progression
TissueMicroarrayComponents
The tissue donation and rapid autopsy programs
was approved by the Institutional Review Board of the
University of Michigan. One hundred ninety cores of
pathologically confirmed prostate tissue from 90
patients were used to construct the TMA used for this
analysis. The cores contained normal, benign prostatic
hyperplasia (BPH), BPH stromal nodules, prostate
intraepithelial neoplasia (PIN), prostatic atrophy,
proliferative inflammatory atrophy (PIA), and both
localized and metastatic prostate cancer tissues. The
component of interest was scored on each fragment
containing heterogeneous tissue. Benign prostate
tissue was acquired by cystoprostatectomy and trans-
urethral resection for benign from 30 patients. Pre-
cancerous (PIN and hyperplasia) and localized disease
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samples were obtained from radical prostatectomy
specimens from patients who had their prostate
removed for prostate cancer. Metastatic samples from
distant tissue sites were acquired through rapid autop-
sy from 10 patients who failed androgen deprivation
therapy. The breakdown for all tissue in the human
prostate cancer progression TMA was; normal n ¼ 27
cores, localized cancer n ¼ 59 cores, metastatic n ¼ 19
cores, G6 n ¼ 8 cores, and G7 n ¼ 27 cores.
TRAMPTissueMicroarrayComponents
We utilized tissue from the TRAMP model [17] to
create a 333 core TMA consisting of tissue from 111
wild-type strain (C57BL/6) matched control animals
and TRAMP mice that were either castrated, sham
operated, or treated with 50-Aza-20-deoxycytidine
(5Aza). 5Aza treatment and surgical orchiectomy were
performed independently or in combination as
described [18]. We considered the majority of TRAMP
mice castrated at 15 weeks of age to recapitulate
CRPC, based on evidence showing greater than 80% of
regressed TRAMP tumors following castration return
after 24 weeks [19]. All tissues evaluated in the present
study, were taken from mice sacrificed at 24 weeks of
age. The TRAMP TMA was assessed independently
for the expression of DNMT1, E2F1, or AR and the
immuno-positive percentage of cores evaluated with
each antibody.
Analysis of E2F1, AR, andDNMT1Protein
ExpressionVia Immunohistochemistry
Both the human prostate cancer TMA and the
TRAMP TMA were evaluated using standard biotin-
avidin complex immunohistochemistry and the fol-
lowing antibodies; DNMT1 (ab19905, Abcam), E2F1
(KH95, Calbiochem) and AR (N-20, Santa Cruz). Two
board certified GU pathologists examined all tissue
cores and scored nuclear DNMT1 immunostaining
on a scale from 0 to 3 (0-none, 1-weak, 2-moderate,
and 3-intense). A mean nuclear intensity (MNI) score
was generated for each pathologically characterized
group from both TMAs. The MNI was calculated for
each cohort by dividing the sum of the nuclear
intensity values (0–3) by the total number of tissue
cores (MNI¼staining intensity score sum/total num-
ber of tissue cores). Statistical significance between
MNI values were obtained using Tukey’s multiple
comparison test.
RESULTS
Analysis of DNMT1Expression inHumanTissues
We have previously reported that the increased
expression of E2F1 protein correlates with reduced AR
protein levels during prostate cancer progression to
CRPC in human samples [3]. Further studies by our
group established the existence of an AR repressive
mechanism controlled by E2F1-dependent activation
of the DNMT1 gene that promotes prostate tumor
progression to CRPC in mice [16,18]. To begin to
establish a patho-physiologic role for DNMT1 in
human prostate cancer and the emergence of CRPC,
we evaluated a human TMA comprised of benign
prostate tissue as well as localized and metastatic
prostate cancer tissue. The MNI scores for DNMT1
staining were determined in 27 cores from normal
prostate tissue, 59 cores with localized prostate cancer,
and 19 metastatic, CRPC cores from distal tissue sites.
DNMT1 nuclear staining significantly increased from
normal to metastatic prostate cancer (Fig. 1A). The
DNMT1 MNI score of 1.95 was significantly
(P < 0.0001) greater in metastatic cores compared to
localized PCa (MNI ¼ 1.05). Normal tissue cores
exhibited the least nuclear staining (MNI ¼ 0.19),
which was significantly (P < 0.0001) lower than levels
observed in either localized or metastatic PCa samples
(P < 0.0001; Fig. 1B).
Further evaluation of this TMA and review of the
associated clinical data revealed significant increase in
MNI scores corresponding to rising Gleason scores.
Tissues with a Gleason score of 7 (G7) showed
significantly (P < 0.05) greater nuclear DNMT1 stain-
ing (MNI ¼ 1.26) than G6 graded cores (MNI ¼ 0.5)
(Fig. 2A and B). Metastatic cancer samples (MNI
¼ 1.95) with the highest nuclear DNMT1 levels were
significantly (P < 0.01) higher than G7 staged local-
ized prostate cancer (Fig. 2B). These data demonstrat-
ed that localized prostate cancer exhibits an increased
DNMT1 MNI score that is associated with increasing
Gleason score. Additionally, nuclear DNMT1 staining
was strongest in metastatic tissues from patients who
also failed androgen-deprivation therapy. These data
demonstrated a positive association between DNMT1
expression and increasing Gleason stage, metastasis
and development of CRPC.
Analysis of ARRegulationThroughthe E2F1/
DNMT1Axis in theTRAMPMouse
We had previously suggested that there existed an
inhibitory axis by which E2F1 and DNMT1 could
repress the transcription of AR during the progression
of prostate tumors in TRAMP mice. To test this
hypothesis, we examined prostate tissue from male
TRAMP mice, in which the retinoblastoma tumor
suppressor (pRb) is inactivated by the prostate-specific
expression of SV-40 large T antigen (LgT), resulting in
increased E2F1 activity in the prostate gland. Prostate
tissue from TRAMP mice with poorly differentiated
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Fig. 1. Nuclear DNMT1 expression during prostate cancer progression. A: Histological representation from a human prostate cancer
progression TMA consisting of normal, localized, and metastatic prostate cancer (magnification; 20 (a^c) and 40 (d^f )). B: Mean
nuclear intensity scores arepresented in a bar graph for each diagnosis (normal n ¼ 27 cores, localized cancer n ¼ 59 cores, andmetastatic
n ¼ 19cores).Tukey’smultiple comparisontestdemonstrates statistical significance (P-value < 0.0001).
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prostate cancer (PD PCa) stained positive for SV-40
LgT, which was absent in tissues from C57BL/6
control mice (Fig. 3A). E2F1 immunoreactivity was
also higher in PD PCa compared to normal tissues
(Fig. 3A). Increased levels of the E2F1 target gene,
PCNA, were used as an indication of both increased
E2F1 activity and cellular proliferation in the TRAMP
tumors. Epithelial cells in control (normal) prostate
tissues were negative for PCNA staining (Fig. 3A),
indicating both low E2F1 activity and a low prolife-
rative index. In contrast, PCNA protein levels were
much higher in poorly differentiated tumor tissue
derived from TRAMP mice at 24 weeks. This increase
in cell proliferation and E2F1 activity was associated
with a concomitant increase in nuclear DNMT1 stain-
ing and subsequent decreases in AR protein. Control
tissues revealed strong AR nuclear staining. These
results demonstrated that increased E2F1 expression
correlated with increased cell proliferation and expres-
sion of E2F-target genes (PCNA and DNMT1) with a
concomitant down-regulation of AR in prostate epithe-
lial cells during prostate cancer progression in the
TRAMP model. Only 4/49 (8.2%) and 5/62 (8.1%) of
the benign tissue cores stained positive for E2F1 and
DNMT1 respectively, while 65/67 (97.0%) of the cores
stained positive for AR. Conversely, a large proportion
of the tissues diagnosed with cancer stained positive
for E2F1 (59/73 (80.8%)) and DNMT1 (80/80 (100%))
compared to (12/67 (17.9%)) of the cores that stained
positive for AR (Fig. 3B). The observation that high
levels of E2F1 and DNMT1 are seen in PD TRAMP
tumors that concomitantly express low levels of AR
continue to support a regulatory role for the repression
of AR transcription by the E2F1/DNMT1 axis in vivo.
Analysis of E2F1,DNMT1, andARin
CRPCof TRAMPMice
To determine if a correlation of AR repression with
increased levels of E2F1 and DNMT1 existed during
the development of CRPC, we compared the immuno-
staining of these proteins in the mouse TMA. Cores
from 5Aza treated and untreated castrated TRAMP
mice, which recapitulate CRPC when castrated at
15 weeks of age were examined. As shown in Figure 4,
we observed a 30% decrease in tissues stained with
DNMT1 from castrated TRAMP mice receiving 5Aza
compared to those treated with PBS. The percent of
Fig. 2. Nuclear DNMT1expression in Gleason 6 and Gleason 7 prostate tumors.A: Nuclear DNMT1staining shown in normal (n ¼ 27
cores),Gleason 6 (G6) (n ¼ 8 cores), and Gleason 7 (G7) (n ¼ 27 cores) prostate cancer, andmetastatic prostate cancer (n ¼ 19 cores).
B: The MNI is represented in a bar graph.Tukey’s multiple comparison test demonstrates statistical significance (G6 vs.G7, P-value < 0.05
andG7vs.metastaticcancer,P-value < 0.01).
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AR positive cores, however, increased by 27% after
5Aza treatments. No apparent changes were observed
in the amount of E2F1 positive tissues taken from
untreated versus 5Aza treated mice. Representative
tissue from castrated TRAMP mice that maintained
normal glandular morphology following 5Aza treat-
ment show intense nuclear AR staining compared to
decreases in DNMT1 (Fig. 4A). These data demon-
strate that AR levels increase in the absence of DNA
methylation and reduced DNMT1 levels in vivo.
DISCUSSION
The molecular events underlying the clinical recur-
rence of CRPC remain vague. Based on our previous
discovery that AR transcription is inhibited through
the E2F1/DNMT1 axis, we set out to establish a
mechanism that reveals a functional association with
CRPC and also provide the first comprehensive
histopathological evaluation of DNMT1 in human
prostate cancer. The significant association between
prostate cancer progression to CRPC and increased
DNMT1 expression supports a plausible utility for
DNMT1 as a diagnostic marker for certain prostate
cancers. A previous study reports that gastric cancer
patients with high epithelial DNMT1 expression have
a significantly higher risk of death [20]. Elevated
DNMT1 expression was additionally shown to indi-
cate the presence of metastatic prostate cancer in the
TRAMP model. Kinney et al. [14] observed a reduction
in prostate cancer metastases after DNMT1 levels were
knocked down in TRAMP mice. Our study reveals
Fig. 3. E2F1, DNMT1, and AR stainingTRAMP tissue.A: Immunohistochemical staining of normal prostate tissue from C57BL/6 control
mice (panelsa^e) at10magnificationandprostate cancer from24weekoldTRAMPmice (panels f^j) at100magnification. Sectionswere
stainedforLargeTag(panels a andf ),PCNA(panelsbandg),E2F1(c andh),DNMT1(dandi), andAR(panelseandj).B:Thepercentageof tissue
cores stainingpositive foreitherE2F1,DNMT1,orARareshownas apercentof the totalamountofcoresevaluatedper antibody.
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DNMT1 expressional changes correlate with stage
(localized vs. metastatic) and histological grade, with
increased intensity for both more advanced disease
and higher grade tumor. The significant difference in
MNI between Gleason grade 6 and 7 is of interest for
potential clinical application in the setting of active
surveillance. There was a relatively even distribution
of Gleason 3 þ 4 (44%) and 4 þ 3 (56%) in our sample
set, however there were only a small number of 4 þ 4
and 4 þ 5 samples for examination and even though
these intensity scores were similar to the Gleason 7
group, the small number of 4 þ 4 and 4 þ 5 samples
lacked sufficient power to draw substantive conclu-
sions. There is an ever expanding repertoire of markers
being applied to evaluate small Gleason 6 and 7 grade
tumors in an effort to triage patients into active
surveillance and definitive treatment categories. There-
fore, DNMT1 staining of prostate biopsy samples
alone or in combination with other markers may be
of clinical value in this setting and deserves further
study.
AR repression is one of several molecular events
observed in CRPC. We have demonstrated the mainte-
nance of AR levels in experimentally induced CRPC
from TRAMP mice after treatments with 5Aza sug-
gesting that AR repression is mediated by DNA
methylation and can be prevented by inhibition of
DNMT activity. AR is known to be methylated in a
Fig. 4. E2F1, DNMT1, and AR expression in theTRAMP CRPC model.A: E2F1 (a,d), DNMT1 (b,e), and AR (c,f ) immunostained cores
represent tissues taken from castrated TRAMP mice treated with either PBS (a^c) or 50 -Aza-20 -deoxycytidine (5Aza) (d^f ). B: The
percentage of E2F1, DNMT1, and AR positive tissues taken from castrated TRAMP animals are shown as a percent of the total number of
tissuecoresanalyzedforeitherPBSor5Aza treatedmice.
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series of metastatic human prostate cancer cell lines. In
addition to being methylated within specific regions,
AR gene expression is rescued in androgen indepen-
dent TSU-PR1 [21] and rat cells [22] after 5Aza
treatments. Kinoshita et al. [23] also identified hyper-
methylated regions within and downstream of the AR
promoter that were common amongst AR negative
castration resistant cell lines. A study of localized
prostate cancer samples revealed that AR gene methyl-
ation was specifically occurring during late stage
prostate cancer [24]. A comparison of prostate cancer
tissues showing AR methylation demonstrated that
100% of the CpG sites analyzed were methylated in
samples from CRPC patients compared to 50% of the
sites being methylated in samples acquired from
localized prostate tumors [25]. These data further
support a mechanism for AR regulation via methyla-
tion in our model of CRPC.
Current studies of AR isoforms have provided
supporting evidence of a functional role for specific
variants in prostate cancer. AR isoforms contain either
C- or N-terminal truncations [26–28]. The AR variants
lacking the C-terminal domain are shown to be
associated with prostate cancer and disease progres-
sion. Expression of the C-terminal truncated AR-V1
and AR-V7 variants were observed at increased levels
in CRPC tissue samples compared to hormone na€ıve
patient tissue [29]. Guo et al. [30] demonstrated that
AR-V7 is reacquired for the proliferation of androgen
independent 22Rv1 cells grown in the absence of
androgens. Less is known about the N-terminal
truncated variants AR-A (87 kDa) and AR45
(45 kDa) [26,27]. The isoforms that lack the trans-
activation domain are shown to disrupt AR activity
and reduce cellular proliferation rates [27,31]. Our
study utilized an N-terminal directed antibody that
fails to recognize the AR-A and AR45 isoforms.
However, all C-terminal truncated variants pertinent
to a study of CRPC are recognized by the antibody.
DNMT1 facilitates genomic silencing by maintain-
ing the state of DNA methylaion but is also known to
utilize de novo pathways. We have previously ob-
served the repression of AR by E2F1 through DNMT1
as an intermediary [16]. Our current study demon-
strated that DNMT1 increases during the progression
of human prostate cancer to metastatic and CPRC
disease. Higher DNMT1 levels may facilitate methyla-
tion dependent silencing and suppression of AR
activity, thus providing a role for DNMT1 in maintain-
ing abnormal levels of methylation. Robert et al. [32]
showed that the down regulation of DNMT1 with
anti-sense oligonucleotides in HCT116 colorectal cells
significantly increased the amount of unmethylated
DNA. High DNMT1 levels and increased genomic
methylation have also been reported during the
metastatic progression of prostate cancer in the murine
TRAMP model [14]. Contrary to these findings, Hoff-
mann et al. [33] reported that DNMT1 is not responsi-
ble for methylation during prostate cancer. However,
this study did not globally assess genome-wide meth-
ylation. DNMT1 may therefore repress AR expression
through methylation during late stage prostate cancer
and CRPC.
The substantial increase in AR and decrease in
DNMT1 following 5Aza treatment in the TRAMP
CRPC model suggests that AR is regulated by DNMT
dependent methylation and may represent a therapeu-
tic target. Methylation inhibitors such as 5Aza, were
shown to be effective in the treatment of myelodis-
plastic disease [34], but the short half-life and high
toxicity of 5Aza is currently prohibitive for patient
treatment. More suitable treatments may utilize less
toxic methylation inhibitors such as Zebularine [35].
Other alternatives might employ the direct targeting of
DNMT1 through the use of siRNA oligonucleotides.
Knockdown of DNMT1 mRNA was shown to
reduce proliferation and increase apoptosis in gastric
carcinoma cell lines [36]; however the delivery
of siRNA oligonucleotides to tumors remains problem-
atic. Future studies will need to be conducted to
fully evaluate the therapeutic potential of DNMT1
as well as the predictive value of DNMT1 in CRPC
disease.
CONCLUSIONS
AR repression through the E2F1/DNMT1 axis may
be a mechanism by which cells maintain an undiffer-
entiated yet aberrantly proliferative state during the
progression to CRPC. We demonstrated that nuclear
DNMT1 like E2F1 increases during the metastatic
progression of human prostate cancer and these
changes coupled with decreases in AR expression are
recapitulated in TRAMP mice with poorly differentiat-
ed prostate cancer. Treating castrated TRAMP mice
with 5Aza provided us with a better understanding of
the molecular changes that occur during the progres-
sion to CRPC. From these data we conclude that
increases in epithelial AR levels following the inhibi-
tion of DNA methylation leads to AR repression that
may require DNMT1 catalytic activity during progres-
sion to CRPC.
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